
CLAIMS

1. Use of a therapeutically effective amount of a pharmaceutical composition in the manufacture of a medicament for treating a mast cell tumor in a subject in need thereof, wherein the pharmaceutical composition comprises a benzenesulfonamide derivative and a pharmaceutically acceptable carrier thereof, wherein the benzenesulfonamide derivative is represented by formula (I) below:



(I),






















or a pharmaceutically acceptable salt thereof,






















wherein R_1 to R_7 are independently selected from the group consisting of H, a C_1-C_6 linear or branched alkyl group, a C_1-C_6 linear or branched alkoxy group, a C_3-C_6 cycloalkyl group, a C_3-C_6 cycloheteroalkyl group, an amino group, and a halo group, or R_6 and R_7 are linked to each other to form a ring, and

wherein the alkyl, alkoxy, cycloalkyl, and cycloheteroalkyl groups and the ring in R_1 to R_7 are independently unsubstituted or substituted with one or more substituents.

2. The use of claim 1, wherein the substituent is selected from the group consisting of phenyl, halo, oxo, ether, hydroxyl, carboxyl, amino, sulfo and sulfonamide group.

3. The use of claim 1, wherein the benzenesulfonamide derivative is at least one selected from the group consisting of *para*-toluene sulfonamide, *ortho*-toluene sulfonamide, *meta*-toluene sulfonamide, N-ethyl-*ortho*-toluene sulfonamide, N-ethyl-*para*-toluene sulfonamide, N-cyclohexyl-*para*-toluene sulfonamide,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,
5


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,
5

,

,

,

,

,

,


,


,


,


,


,




,


,


,


,


,


,

and any combination thereof.

4. The use of claim 1, wherein the benzenesulfonamide derivative is *para*-toluene sulfonamide, *ortho*-toluene sulfonamide, or *meta*-toluene sulfonamide.

5. The use of claim 1, wherein the pharmaceutically acceptable carrier is at least one selected from the group consisting of a filler, a binder, a preservative, a disintegrating agent, a lubricant, a suspending agent, a wetting agent, a biocompatible solvent, a penetration enhancer, a surfactant, a thickening agent, an acid, a flavoring agent, a complexing agent, and any combination thereof.

6. The use of claim 1, wherein the pharmaceutically acceptable carrier is at least one selected from the group consisting of alkylene glycol, sebacic acid, dimethyl sulfoxide, ethanol, and any combination thereof.

7. The use of claim 6, wherein the alkylene glycol is at least one selected from the group consisting of polyethylene glycol, propylene glycol, hexylene glycol, and any combination

thereof.

8. The use of claim 1, wherein the benzenesulfonamide derivative is present in an amount of from 1% to 50% by weight of the pharmaceutical composition.

9. The use of claim 8, wherein the benzenesulfonamide derivative is present in an amount of from 20% to 40% by weight of the pharmaceutical composition.

10. The use of claim 1, wherein the pharmaceutical composition further comprises at least one of 1% to 50% by weight of polyethylene glycol 400, 1% to 10% by weight of 1,2-propylene glycol, 1% to 10% by weight of sebacic acid, 1% to 20% by weight of 2-ethyl-1,3-hexanediol, 0% to 20% by weight of dimethyl sulfoxide, and 0% to 20% by weight of ethanol.

11. The use of claim 1, wherein the medicament causes ablation of the mast cell tumor in the subject.

12. The use of claim 1, wherein the mast cell tumor is a canine mast cell tumor, a feline mast cell tumor, an equine mast cell tumor, a cattle mast cell tumor, or a sheep mast cell tumor.

13. The use of claim 1, wherein the mast cell tumor is a cutaneous mast cell tumor or a visceral mast cell tumor.

14. The use of claim 1, wherein the subject is selected from the group consisting of a rodent, a murine, a monkey, a guinea pig, a dog, a cat, a cow, a sheep, a pig, a horse, a rabbit, and a human.

15. The use of claim 1, wherein the benzenesulfonamide derivative in the pharmaceutical composition is to be administered to the subject in a therapeutically effective amount of from about 33 mg/day to about 10,000 mg/day.

16. The use of claim 1, wherein the benzenesulfonamide derivative in the pharmaceutical composition is to be administered to the subject in a therapeutically effective amount of from about 165 mg/day to about 3,300 mg/day.

17. The use of claim 1, wherein the benzenesulfonamide derivative in the pharmaceutical composition is to be administered to the subject in a therapeutically effective amount of from about 330 mg/day to about 1,650 mg/day.

18. The use of claim 1, wherein the benzenesulfonamide derivative in the pharmaceutical composition is to be administered to the subject in a therapeutically effective amount of from about 33 mg to about 26,400 mg during a treatment period or a treatment cycle.

19. The use of claim 1, wherein the pharmaceutical composition is to be administered to the subject intratumorally, intravenously, subcutaneously, intradermally, orally, intrathecally, intraperitoneally, intranasally, intramuscularly, intrapleuraly, topically, or through nebulization.

20. The use of claim 1, wherein the pharmaceutical composition is in a form selected from the group consisting of an injection formulation, a dry powder, a tablet, an oral liquid, a flake, a film, a lozenge, a capsule, a granule, a pill, a gel, a lotion, an ointment, an emulsifier, a paste, a cream, an eye drop, and a salve.